Article
Characterization of hepatitis C virus (HCV) quasispecies dynamics upon short-term dual therapy with the HCV NS5B nucleoside polymerase inhibitor mericitabine and the NS3/4 protease inhibitor danoprevir.
Antimicrobial agents and chemotherapy - 1 Nov 2012
Le Pogam S, Yan J M, Chhabra M, Ilnicka M, Kang H, Kosaka A, Ali S, Chin D J, Shulman N S, Smith P, Klumpp K, Nájera I
Abstract excerpt
In the INFORM-1 study, 73 patients with chronic hepatitis C virus infection received mericitabine plus danoprevir for up to 13 days. Seventy-two patients experienced a continuous decline in HCV RNA levels during treatment, and of these patients, 14 had viral loads that remained >1,000 IU/ml by day 13 and 1 met the definition for viral breakthrough. In-depth NS5B and NS3/4A population and clonal sequencing studies...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.